IL201476A - Factor D Antagonist Antibody for Use in the Prevention and Treatment of Ophthalmic-Related Ocular Diseases - Google Patents

Factor D Antagonist Antibody for Use in the Prevention and Treatment of Ophthalmic-Related Ocular Diseases

Info

Publication number
IL201476A
IL201476A IL201476A IL20147609A IL201476A IL 201476 A IL201476 A IL 201476A IL 201476 A IL201476 A IL 201476A IL 20147609 A IL20147609 A IL 20147609A IL 201476 A IL201476 A IL 201476A
Authority
IL
Israel
Prior art keywords
complement
antibodies
prevention
factor
treatment
Prior art date
Application number
IL201476A
Other languages
English (en)
Hebrew (he)
Other versions
IL201476A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL201476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL201476A0 publication Critical patent/IL201476A0/en
Publication of IL201476A publication Critical patent/IL201476A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
IL201476A 2007-05-23 2009-10-13 Factor D Antagonist Antibody for Use in the Prevention and Treatment of Ophthalmic-Related Ocular Diseases IL201476A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (2)

Publication Number Publication Date
IL201476A0 IL201476A0 (en) 2010-05-31
IL201476A true IL201476A (en) 2016-11-30

Family

ID=39638868

Family Applications (2)

Application Number Title Priority Date Filing Date
IL201476A IL201476A (en) 2007-05-23 2009-10-13 Factor D Antagonist Antibody for Use in the Prevention and Treatment of Ophthalmic-Related Ocular Diseases
IL248552A IL248552A0 (en) 2007-05-23 2016-10-27 Prevention and treatment of related eye conditions - complementary

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL248552A IL248552A0 (en) 2007-05-23 2016-10-27 Prevention and treatment of related eye conditions - complementary

Country Status (28)

Country Link
US (6) US8007791B2 (en:Method)
EP (1) EP2152755B1 (en:Method)
JP (4) JP5416695B2 (en:Method)
KR (1) KR101540126B1 (en:Method)
CN (3) CN101754980B (en:Method)
AR (1) AR066660A1 (en:Method)
AU (1) AU2008256835B2 (en:Method)
BR (1) BRPI0811142A8 (en:Method)
CA (1) CA2683498A1 (en:Method)
CL (1) CL2008001498A1 (en:Method)
CY (1) CY1116062T1 (en:Method)
DK (1) DK2152755T3 (en:Method)
ES (1) ES2533242T3 (en:Method)
HK (1) HK1207327A1 (en:Method)
HR (1) HRP20150281T1 (en:Method)
IL (2) IL201476A (en:Method)
MX (1) MX2009012422A (en:Method)
PE (1) PE20090294A1 (en:Method)
PH (1) PH12013500992B1 (en:Method)
PL (1) PL2152755T3 (en:Method)
PT (1) PT2152755E (en:Method)
RS (1) RS53901B1 (en:Method)
RU (2) RU2522976C2 (en:Method)
SG (1) SG10201401404RA (en:Method)
SI (1) SI2152755T1 (en:Method)
TW (2) TW201417829A (en:Method)
WO (1) WO2008147883A1 (en:Method)
ZA (1) ZA200907028B (en:Method)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
KR20130137716A (ko) 2005-11-04 2013-12-17 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20110058866A (ko) * 2008-09-02 2011-06-01 노파르티스 아게 비시클릭 키나제 억제제
SG2014007389A (en) 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
HRP20211909T1 (hr) * 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
EP2635704B1 (en) 2010-11-01 2017-04-19 F. Hoffmann-La Roche AG Predicting progression to advanced age-related macular degeneration using a polygenic score
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012103165A2 (en) * 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
CN105121429B (zh) 2012-06-28 2017-12-12 诺华股份有限公司 补体途径调节剂和其用途
ES2648962T3 (es) 2012-06-28 2018-01-09 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la vía del complemento
BR112015000578A2 (pt) 2012-07-12 2017-06-27 Novartis Ag moduladores da via do complemento e usos dos mesmos
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
WO2014160884A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP2016539098A (ja) * 2013-10-25 2016-12-15 チルドレンズ メディカル センター コーポレーション 網膜の血管障害を治療又は予防する方法
US10179821B2 (en) * 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
MX391052B (es) * 2015-09-23 2025-03-21 Sangamo Therapeutics Inc Represores de htt y usos de estos.
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
AU2016344146A1 (en) 2015-10-30 2018-05-10 Genentech, Inc. Methods of measuring Factor D activity and potency of Factor D inhibitors
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
HRP20211608T1 (hr) * 2015-12-23 2022-01-21 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CN110461879B (zh) * 2017-02-10 2024-03-29 宾夕法尼亚大学理事会 抗因子d抗体及其用途
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO1999046281A2 (en) 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
WO1999042133A1 (en) * 1998-02-20 1999-08-26 Tanox, Inc. Inhibitors of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2340794A1 (en) 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468977B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
AU770332B2 (en) * 1998-12-21 2004-02-19 Vegenics Limited Antibodies to truncated VEGF-D and uses thereof
EP1141284A2 (en) 1998-12-22 2001-10-10 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
IL145310A0 (en) 1999-03-11 2003-01-12 Rmf Dictagene Sa Vascular adhesion molecules and modulation of their function
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1423601A (en) 1999-11-02 2001-05-30 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
KR20130137716A (ko) * 2005-11-04 2013-12-17 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
CA2683498A1 (en) 2008-12-04
CL2008001498A1 (es) 2009-06-12
RS53901B1 (sr) 2015-08-31
CY1116062T1 (el) 2017-02-08
PH12013500992B1 (en) 2018-12-14
MX2009012422A (es) 2009-12-04
KR20100033973A (ko) 2010-03-31
WO2008147883A8 (en) 2013-05-23
WO2008147883A1 (en) 2008-12-04
US20130052685A1 (en) 2013-02-28
JP5416695B2 (ja) 2014-02-12
CN104367999A (zh) 2015-02-25
PH12013500992A1 (en) 2016-01-25
IL201476A0 (en) 2010-05-31
JP2017197577A (ja) 2017-11-02
US8497094B2 (en) 2013-07-30
IL248552A0 (en) 2016-12-29
ES2533242T3 (es) 2015-04-08
US20130302333A1 (en) 2013-11-14
US20160272726A1 (en) 2016-09-22
RU2522976C2 (ru) 2014-07-20
CN107096029B (zh) 2021-02-26
EP2152755A1 (en) 2010-02-17
SG10201401404RA (en) 2014-08-28
EP2152755B1 (en) 2014-12-31
HRP20150281T1 (hr) 2015-04-10
JP2014087346A (ja) 2014-05-15
US20090181017A1 (en) 2009-07-16
US20110282034A1 (en) 2011-11-17
ZA200907028B (en) 2010-12-29
SI2152755T1 (sl) 2015-05-29
BRPI0811142A8 (pt) 2018-12-18
CN101754980B (zh) 2014-10-29
PT2152755E (pt) 2015-04-01
CN101754980A (zh) 2010-06-23
HK1207327A1 (en) 2016-01-29
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
RU2014113046A (ru) 2015-10-10
HK1139161A1 (en) 2010-09-10
CN107096029A (zh) 2017-08-29
PL2152755T3 (pl) 2015-06-30
PE20090294A1 (es) 2009-03-27
TWI419704B (zh) 2013-12-21
US8268310B2 (en) 2012-09-18
AU2008256835A1 (en) 2008-12-04
AR066660A1 (es) 2009-09-02
KR101540126B1 (ko) 2015-07-28
DK2152755T3 (en) 2015-03-02
US8007791B2 (en) 2011-08-30
US20180079826A1 (en) 2018-03-22
TW200904471A (en) 2009-02-01
RU2009147744A (ru) 2011-06-27
TW201417829A (zh) 2014-05-16
JP2016145205A (ja) 2016-08-12
JP2010528047A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
IL201476A (en) Factor D Antagonist Antibody for Use in the Prevention and Treatment of Ophthalmic-Related Ocular Diseases
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
EP1987065A4 (en) METHOD FOR IMPROVING THE IMMUNE FUNCTION AND METHOD FOR PREVENTING OR TREATING DISEASES IN MAMMALS
EP2142213A4 (en) METHOD FOR INHIBITING COMPLEMENTATION ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND THEIR USE
EP2303918A4 (en) METHOD FOR DOSED ADMINISTRATION OF A ACTIVIN ACTRIIA ANTAGONIST AND OBSERVATION OF TREATED PATIENTS
PT2471441T (pt) Método e dispositivo para determinar a posição do ponto de rotação do olho
EP2010111A4 (en) DEVICE AND METHOD FOR THE TREATMENT OF GROWN NAILS
ZA201108586B (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
SI2470191T1 (sl) Postopki in sestavki za prepreäśevanje ali zdravljenje oftalmoloĺ kih stanj
IL210385A0 (en) Ophthalmic device having therapeutic agent delivery capability and method of forming same
SMT202300082T1 (it) Metodi e composizioni per il trattamento dei disturbi associati al complemento
IL213852A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
ZA200905101B (en) Diagosis and treatment of preeclampsia
ZA200904806B (en) Prevention and treatment of sub-clinical pcvd
IL210755A0 (en) Devices and methods for forming tracts in tissue
ZA200900210B (en) Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
LT2576782T (lt) Sirnr ir jų panaudojimas būduose ir kompozicijose skirtose akių ligų gydymui ir (arba) prevencijai
ZA200903610B (en) Non-resorbable implantable guides and methods of use
PL2056799T3 (pl) Kompozycje i sposoby do leczenia lub zapobiegania jaskrze lub jej rozwojowi
GB0617505D0 (en) Pneumothorax treatment apparatus and methods
EP2019590A4 (en) METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED CONDITIONS AND CONDITIONS
TWI346840B (en) Preventing device and method for sensitive-liquid in slit-nozzle
ZA200904382B (en) Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed